跳至主要内容
临床试验/EUCTR2006-005386-19-BE
EUCTR2006-005386-19-BE进行中(未招募)1 期

Cytokines and inflammatory proteins gene expression study in synovial biopsies from rheumatoid arthritis patients refractory to anti-TNF therapy treated with Rituximab - Anti TNF resistant RA / RTX / mini

Cliniques Universitaires Saint-Luc0 个研究点目标入组 20 人开始时间: 2006年11月3日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Diagnosis of RA (according to ACR criteria)
  • Active RA defined by a DAS28-CRP score > 5.1 or >3.2 with a swollen joint count = 8
  • Presence of knee arthralgia or synovitis
  • Failure to at least one TNF blocker (Remicade, Enbrel, Humira)
  • Stable therapy with MTX, corticosteroïds or NSAIDs
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Previous Rituximab treatment
  • Exclusion for general safety (history of severe allergic reaction, sepsis, malignancy within 5 years, pregnancy, severe heart failure)
  • Excluded Concomitant Medications :
  • Concurrent treatment with other DMARDs than MTX or any anti-TNF and biological therapies. Enbrel, Remicade and Humira should be respectively stopped 4, 8 and 8 weeks before inclusion.

研究者

相似试验

Cytokines and inflammatory proteins gene expression... | 临床试验